Taiho to file colorectal cancer combo following positive PhIII data
This article was originally published in Scrip
Executive Summary
Taiho Pharmaceutical, a subsidiary of Japanese major Otsuka, is planning US and EU filings following the release of top-line results from a Phase III study of its metastatic colorectal cancer (mCRC) drug TAS-102.